Conflict of interest L. Brochez has been paid as a consultant by Abbott, Pfizer. J. Lambert has served as consultant and/or paid speaker for and/or participated in clinical trials sponsored by companies that manufacture drugs used for the treatment of psoriasis including Abbott, Celgene, Centocor, Janssen-Cilag, LEO Pharma, Pfizer (formerly Wyeth). The other authors declare no conflicts of interest.
A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis
Article first published online: 28 DEC 2012
© 2012 The Authors. Journal of the European Academy of Dermatology and Venereology © 2012 European Academy of Dermatology and Venereology
Journal of the European Academy of Dermatology and Venereology
Volume 28, Issue 4, pages 507–511, April 2014
How to Cite
Bostoen, J., Van Praet, L., Brochez, L., Mielants, H. and Lambert, J. (2014), A cross-sectional study on the prevalence of metabolic syndrome in psoriasis compared to psoriatic arthritis. Journal of the European Academy of Dermatology and Venereology, 28: 507–511. doi: 10.1111/jdv.12071
Funding sources The study has been financially supported by Abbott.
- Issue published online: 18 MAR 2014
- Article first published online: 28 DEC 2012
- Received: 6 August 2012; Accepted: 15 November 2012
Background Increasing epidemiological evidence suggests associations between psoriasis, psoriatic arthritis (PsA) and metabolic disease. Elucidating the complex relationship between these comorbidities may have important management implications.
Objective The aim of this study was to examine the difference in prevalence of metabolic disease burden between patients with psoriasis who lack arthritic manifestations (PsO) and PsA patients.
Methods We performed a cross-sectional study in 123 patients with PsO and PsA. Metabolic syndrome was defined using the new criteria developed by the International Diabetes Foundation (IDF) in 2004. Therefore, clinical examination and standard survey were performed and fasting blood samples were collected.
Results One hundred and four patients were analysed, of which 49 were PsO and 55 were PsA patients. We found that prevalence of the metabolic syndrome according to the IDF criteria was significantly higher in the PsO (44.9%) compared with the PsA group (25.5%) (P = 0.037). Looking closer at the individual components of the metabolic syndrome, this difference can mainly be attributed to the significantly higher prevalence of abdominal obesity in PsO (83.7%) vs. PsA (65.5%) (P = 0.034). For other individual components of the metabolic syndrome such as triglycerides, high-density lipoproteins, hypertension and plasma glucose, we could not show statistically significant differences between the groups.
Conclusion Metabolic syndrome is more prevalent in patients with PsO than in PsA patients, mainly determined by the higher prevalence of abdominal obesity in PsO compared with PsA group.